PharmAthene, Inc. (PIP) ended last trading session with a change of -1.88 percent. It trades at an average volume of 4.47M shares versus 2.25M shares recorded at the end of last trading session. The share price of $0.86 is at a distance of 81.91 percent from its 52-week low and down -75.57 percent versus its peak. The company has a market cap of $57.62M and currently has 67.39M shares outstanding. The share price is currently -5.93 percent versus its SMA20, -60.4 percent versus its SMA50, and -66.65 percent versus its SMA200. The stock has a weekly performance of 29.84 percent and is -73.69 percent year-to-date as of the recent close.
On Jan. 19, 2017 PharmAthene, Inc. (PIP) and Altimmune, Inc., a privately-held immunotherapeutics company targeting infectious diseases, announced the signing of a definitive agreement for the merger of PharmAthene and Altimmune in an all-stock transaction. Altimmune’s current investors include Novartis Venture Fund, HealthCap, Truffle Capital and Redmont Capital. The combined company will be a fully-integrated and diversified immunotherapeutics company with four clinical stage and one preclinical stage programs. The proposed transaction does not affect PharmAthene’s previously announced special one-time cash dividend of $2.91 per share of common stock.
Calithera Biosciences, Inc. (CALA) recently recorded 19.34 percent change and currently at $14.5 is 559.09 percent away from its 52-week low and down 5.84 percent versus its peak. It has a past 5-day performance of 23.93 percent and trades at an average volume of 795.88K shares. The stock has a 1-month performance of 63.84 percent and is 346.15 percent year-to-date as of the recent close. There were about 21.64M shares outstanding which made its market cap $313.78M. The share price is currently 42.58 percent versus its SMA20, 97.68 percent versus its SMA50, and 228.49 percent versus its SMA200.
March 10, 2017 — Calithera Biosciences, Inc. (CALA), a clinical-stage pharmaceutical company focused on discovering and developing novel small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer, announced that the Company’s fourth quarter and year-end 2016 financial results will be released on Thursday, March 16, 2017. Company management will host a conference call on Thursday, March 16, 2017 at 1:30 p.m. Pacific Time/ 4:30 p.m. Eastern Time to discuss the financial results and other recent corporate highlights.